- Antibiotic developer Motif Bio said it was presenting data on the skin treatment iclaprim at an industry conference in Lisbon.

The safety study data was being presented at the European Society of Clinical Microbiology and Infectious Diseases/American Society for Microbiology Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, being held September 4-7.

'We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA, that cause severe skin infections,' chief medical officer David Huang said.

'With its targeted Gram-positive spectrum of activity, low propensity for resistance development, favourable tolerability profile and efficacy results, we think that, if approved, iclaprim could be an important new treatment option for patients with ABSSSI.'

Story provided by